NCT01688492View on ClinicalTrials.gov

Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions
Prostate Cancer
Interventions
DRUG

Ipilimumab

Abiraterone acetate (JanssenBiotech, Inc/Johnson \& Johnson) 1000 mg orally daily plus prednisone 5 mg orally twice daily will be administered continuously during the duration of the trial. Starting at cycle 3 (Combination Therapy), Ipilimumab (Bristol-Myers Squibb) will be infused intravenously (IV) once every 3 weeks for a total of 4 infusions.

Trial Locations (3)

10065

Memorial Sloan Kettering Cancer Center, New York

60208

Northwestern University, Evanston

97239

Oregon Health & Science University, Portland

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Northwestern University

OTHER

collaborator

Oregon Health and Science University

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT01688492 - Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer | Biotech Hunter | Biotech Hunter